Schlossmacher Lab

Michael Schlossmacher profile picture

Contact Information

Michael Schlossmacher, MD, DABPN, FRCPC

Administrative Assistant:
Nancy MacDonald

For those interested in a position in the laboratory, please contact:
Dr. Julianna Tomlinson


Unravelling the mystery of how one gene contributes to Parkinson’s, Crohn’s and leprosy
September 25, 2019 - Researchers have struggled for years to understand how mutations in one gene, called LRRK2, can increase the risk of three very different diseases: Parkinson’s (a brain disease), Crohn’s (a gut disease) and leprosy (a peripheral nervous system ...
Researchers honoured for outstanding work in Parkinson’s, critical care and surgery
April 11, 2019 - A number of outstanding researchers and research teams were recognized at The Ottawa Hospital’s Excellence Awards Ceremony on April 11. They include the Parkinson Research Consortium, the Operating Room Black Box® Research Program and ICU ...
Brain Health Awareness Week: October 15-19
October 10, 2018 - Researchers, clinicians, patients and members of the general public are invited to take part in Brain Health Awareness Week from October 5-19, hosted by the University of Ottawa Brain and Mind Research Institute, in collaboration with The Ottawa ...
Award-winning scientist challenges medical dogma in quest to prevent, treat neurodegenerative disease
October 25, 2017 - Dr. Michael Schlossmacher grew up in Austria, trained at Harvard and now leads The Ottawa Hospital’s neuroscience research program. His research helped establish a key concept in Alzheimer’s disease and led to a clinical trial of an experimental ther
Parkinson’s-related protein also protects against infections
June 14, 2017 - Scientists have known for more than a century that Parkinson’s disease is associated with strange clumps of protein in the brain. Twenty years ago, researchers found that these clumps are mainly made of a protein called alpha-synuclein, but the nor
Grant helps researchers better study important young-onset Parkinson’s protein
January 25, 2017 - Dr. Michael Schlossmacher and BioLegend Inc.’s Dr. Peggy Taylor were awarded $200,000 USD by The Michael J. Fox Foundation for Parkinson’s Research to create research tools that can identify various forms of a specific brain protein that is ...
Weston grants to accelerate development of new therapies for Parkinson disease and related dementias
November 26, 2014 - Drs. Michael Schlossmacher and Julianna Tomlinson and their colleagues have been awarded $300,000 from the Weston Brain Institute for two research projects aimed at developing new therapies for Parkinson disease and dementia with Lewy bodies. These p